youtube_live
Q3 2026 earnings • in 5 days
See detailschevron_right
EDIT:NASDAQ
Editas Medicine Inc
2,55 US$
arrow_downward
-6,25%(-0,17) 1D
2,53 US$
arrow_downward
-0,78% (-0,020)bedtimeAfter hours
Closed: 5 ნოე, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
2,68 US$
High
2,68 US$
Low
2,41 US$
Mkt. cap
391,63 მლნ.
Avg. vol.
2,35 მლნ.
Volume
2,10 მლნ.
52-wk high
3,94 US$
52-wk low
1,66 US$
EPS
-0,74 US$
Beta
2,09
Shares outstanding
153,58 მლნ.
No. of employees
87
Open
2,68 US$
High
2,68 US$
Low
2,41 US$
Mkt. cap
391,63 მლნ.
Avg. vol.
2,35 მლნ.
Volume
2,10 მლნ.
52-wk high
3,94 US$
52-wk low
1,66 US$
EPS
-0,74 US$
Beta
2,09
Shares outstanding
153,58 მლნ.
No. of employees
87
News stories
From web sources and news partners
Zacks
·
10 საათის წინ
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
Investing.com
·
12 საათის წინ
Jones Trading initiates Editas Medicine stock coverage with buy rating
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc